Navigation Links
Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients
Date:11/8/2010

INDIANAPOLIS, Nov. 8, 2010 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Voluntis S.A. announced today the introduction of CoaguChek(R) Link, a versatile online resource that helps simplify and streamline the process of managing patients on anticoagulation therapy.

The web-based application gives patients who self-test their PT/INR (clotting time) a simple, convenient way to report their test results and gives doctors a single, secure site to access data to more effectively monitor and manage their patients on warfarin therapy. It is available to physicians who prescribe a patient self-testing program through CoaguChek Patient Services (CPS), an Independent Diagnostic Testing Facility that provides support services for physicians and their patients. The application is based on the Medpassport platform developed by Voluntis, a healthcare software company specializing in Patient Relationship Management.

"CoaguChek Link helps doctors and their patients stay connected so they can work together to manage the patient's anticoagulation therapy more effectively, whether the patient is at home or away," said Tim Huston, director of marketing, professional diagnostics at Roche Diagnostics Corporation. "It simplifies the process for everyone, facilitates better therapy management, and contributes to the goal of helping improve patient outcomes."

CoaguChek Link offers healthcare providers a convenient patient management resource, helping to simplify documentation and streamline office workflow so they can focus on patients that require follow-up care. Clinics and physician offices can use the application (coagucheklink.com) to quickly enroll patients with CPS, educate them about their therapy, view test results in real time through a password-protected portal, modify recommended test frequency or acceptable ranges for patient test results, and generally access the information needed to monitor and adjust a patient's anticoagulant therapy from anywhere. If a patient doesn't report results according to schedule or the results are outside of the range the doctor specifies, the system automatically flags it and the patient's healthcare provider and CPS clinical specialists are notified.

The patient portal of CoaguChek Link helps empower patients to take a more active role in their anticoagulation therapy. At their convenience, enrolled patients can simply log in to the site to report their test results, order supplies, update their profile information, or learn more about their own therapy and the importance of testing.

"CoaguChek Link will give our healthcare providers greater flexibility and an expanded range of options," said Howard Sams, director of business operations at CoaguChek Patient Services. "It will help streamline and simplify the process of monitoring test results, which can help free up physicians to focus on managing patient therapy more effectively."

"We are delighted to have the opportunity to contribute to the continued success of CoaguChek Patient Services in the USA," said Pierre Leurent, Founder and CEO of Voluntis. "This program exemplifies our vision for Voluntis solutions: leading-edge, proven and secure technologies that have the potential to help improve patient care."

About CoaguChek Patient ServicesCoaguChek Patient Services (CPS) is an Independent Diagnostic Testing Facility (IDTF) that provides comprehensive support services for healthcare providers and their anticoagulation patients who perform self-testing. CPS is part of Roche Insulin Delivery Systems, which is accredited by the Joint Commission and has received its Gold Seal of Approval™ for complying with the highest national standards for safety and quality of care.

About VoluntisVoluntis is a healthcare software company specialized in Patient Relationship Management (PRM), its flagship product is called Medpassport. Its mission is to empower healthcare organizations (pharmaceutical and medical companies, insurers and employers, healthcare service providers) to deliver outstanding patient monitoring and support services, using state-of-the-art information and communication technologies. Since 2003, Medpassport has been deployed in Europe and the USA, to manage over 550,000 patient records in over 15 therapeutic areas, including diabetes, respiratory and cardiovascular diseases, oncology, nutrition and sports medicine. Voluntis is a certified ISO 9001:2008 and ISO 13485:2003 company. Voluntis is headquartered in Paris, France, and has offices in Washington DC, USA. To learn more: www.voluntis.com/?lang=en.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

Coagucheklink.com does not provide automated treatment decisions and is not a substitute for professional medical advice.

All trademarks used or mentioned in this release are protected by law.For further information, please contact: RocheBetsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN, USA(317) 521-3911betsy.cox@roche.comVoluntisManon Chevassut / Gaelle Ryouq

Media Relations, Presse-Papiers Agency+33 (0)1 46 99 69 62manon.chevassut@pressepapiers.fr / gaelle.ryouq@pressepapiers.fr
'/>"/>

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Fourth Quarter and Year-End Results
2. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
3. Roche Introduces Immunoassay Module for cobas® 8000 Modular Analyzer Series In U.S.
4. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
5. Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test
6. Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management
7. Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer
8. Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
9. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
10. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
11. Roche Launches New Initiative - Roche Goes to Town
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... June 9, 2017 AirXpanders, Inc. (ASX: AXP) ... the design, manufacture, sale and distribution of the AeroForm® ... progress of its commercial roll-out in the ... more than one hundred (100) medical institutions and health ... offers a needle-free alternative for women who choose reconstructive ...
(Date:6/8/2017)... June 8, 2017  Less than a month ago, ... than 200,000 companies, including hospital networks, in over 150 ... one of the largest online extortion attempts ever recorded. ... market, it is imperative that providers understand where the ... from this — and many other very real cyber ...
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... ... A June 12 article in The Star offers the advice ... oral hygiene by an aged parent who had recently suffered a series of minor ... steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles Area dental ...
(Date:6/20/2017)... ... June 20, 2017 , ... United Benefit Advisors (UBA), the ... Awards (pronounced you-bee) for 2017. The award honors Partner Firms, Principals, agency ... UBA, the clients they serve, and the benefits insurance industry as a whole. ...
(Date:6/20/2017)... ... , ... Fresenius Vascular Care, a national network of outpatient vascular care and ... wide range of vascular conditions, has today announced its new name, Azura Vascular Care, ... more than 40 local brands, a phased rollout of the new brand across all ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... 20, 2017 , ... As a leading dental practice, Wall Centre Dental supports ... disease. Those with bleeding gums in Vancouver, BC, may be developing gingivitis, the first ... heart disease, stroke and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer ...
Breaking Medicine News(10 mins):